Teva Pharmaceutical Industries (TEVA) PT Set at $20.00 by Deutsche Bank

Teva Pharmaceutical Industries (NYSE:TEVA) received a $20.00 target price from analysts at Deutsche Bank in a note issued to investors on Friday. The firm presently has a “hold” rating on the stock. Deutsche Bank’s price target would indicate a potential upside of 15.61% from the company’s previous close.

Several other analysts have also recently commented on the company. BidaskClub raised Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 13th. Gabelli reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 13th. UBS reissued a “neutral” rating and issued a $19.00 price target on shares of Teva Pharmaceutical Industries in a report on Thursday, September 14th. Maxim Group reissued a “hold” rating and issued a $15.50 price target on shares of Teva Pharmaceutical Industries in a report on Thursday, September 14th. Finally, BTIG Research reissued a “buy” rating and issued a $24.00 price target on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 4th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus price target of $20.57.

Teva Pharmaceutical Industries (NYSE:TEVA) traded up $1.60 during trading on Friday, reaching $17.30. The company’s stock had a trading volume of 113,804,800 shares, compared to its average volume of 16,294,546. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.31. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The firm has a market cap of $15,951.20, a PE ratio of 3.63 and a beta of 0.55.

A number of institutional investors have recently added to or reduced their stakes in TEVA. Schwab Charles Investment Management Inc. increased its position in Teva Pharmaceutical Industries by 7.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after buying an additional 17,116 shares in the last quarter. Boston Partners grew its position in shares of Teva Pharmaceutical Industries by 32.6% in the second quarter. Boston Partners now owns 141,852 shares of the company’s stock valued at $4,712,000 after purchasing an additional 34,846 shares during the period. First Trust Advisors LP grew its position in shares of Teva Pharmaceutical Industries by 10.5% in the second quarter. First Trust Advisors LP now owns 612,724 shares of the company’s stock valued at $20,355,000 after purchasing an additional 58,414 shares during the period. Advisors Asset Management Inc. grew its position in shares of Teva Pharmaceutical Industries by 37.6% in the second quarter. Advisors Asset Management Inc. now owns 33,430 shares of the company’s stock valued at $1,111,000 after purchasing an additional 9,136 shares during the period. Finally, Ballentine Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at $582,000. 52.05% of the stock is owned by institutional investors.

WARNING: “Teva Pharmaceutical Industries (TEVA) PT Set at $20.00 by Deutsche Bank” was originally reported by American Banking and Market News and is owned by of American Banking and Market News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/15/teva-pharmaceutical-industries-teva-pt-set-at-20-00-by-deutsche-bank.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.